Literature DB >> 6264140

Irreversible conversion of the physical state of herpes simplex virus preceding inactivation by thermal or antibody treatment.

K Yanagi.   

Abstract

The buoyant density characteristics of infectious particles of herpes simplex virus types 1 and 2 were studied by centrifugation in sucrose and cesium chloride density gradients with a high resolution and satisfactory infectivity recovery. It was shown that two populations of infectious virions differing in buoyant density coexisted, the difference being slight but definite. The ratio of heavy (H) to light (L) viral particles varied depending upon the solute used, the strains of virus, and the cell origin. Circumstances favoring degradation of viral infectivity tended to increase the H portion. Incubation at 37 degrees C largely converted L to H, and heating at 45 degrees C converted all virions to H without infectivity. The L to H conversion was irreversible, and no populations intermediate between L and H were clearly observed. Inactivation by UV light irradiation did not affect the density pattern. That H was not an artefact due to penetration of solutes, osmotic pressure, viral aggregation, or loss of the envelope was shown experimentally. A difference in the outer shape of particles between negatively stained L and H populations was demonstrated by electron microscopy. Both cell-released and cell-bound herpes simplex virus particles gave essentially the same result with respect to the above characteristics. The effect of limiting dilutions of antiserum was similar to that of mild thermal treatment, in that denser virions increased parallel to a decrease in less dense virions. Sensitization with early immunoglobulin G, composed mainly of complement-requiring neutralizing antibody, caused the density transition, and subsequent addition of complement resulted in a further increase in the buoyant density of the sensitized virions. The DNA in virus particles neutralized with immunoglobulin G plus complement remained resistant to DNase treatment. Possible implications of the phenomena are discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6264140      PMCID: PMC171204     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Fractionation of biologically active and inactive populations of human rhinovirus type 2.

Authors:  B D Korant; K Lonberg-Holm; F H Yin; J Noble-Harvey
Journal:  Virology       Date:  1975-02       Impact factor: 3.616

2.  Proteins specified by herpes simplex virus. 8. Characterization and composition of multiple capsid forms of subtypes 1 and 2.

Authors:  W Gibson; B Roizman
Journal:  J Virol       Date:  1972-11       Impact factor: 5.103

3.  Characterization of type 1 poliovirus by electrophoretic analysis.

Authors:  B Mandel
Journal:  Virology       Date:  1971-06       Impact factor: 3.616

4.  Separation of various blood cells in colloidal silica-polyvinylpyrrolidone gradients.

Authors:  H Pertoft; O Bäck; K Lindahl-Kiessling
Journal:  Exp Cell Res       Date:  1968-05       Impact factor: 3.905

5.  Structural proteins of herpes simplex virus.

Authors:  D J Robinson; D H Watson
Journal:  J Gen Virol       Date:  1971-02       Impact factor: 3.891

6.  Density gradient centrifugation of a herpesvirus (IBRV) in colloidal silica.

Authors:  H Pertoft
Journal:  Virology       Date:  1970-06       Impact factor: 3.616

7.  Immune virolysis: effect of antibody and complement on C-type RNA virus.

Authors:  S Oroszlan; R V Gilden
Journal:  Science       Date:  1970-06-19       Impact factor: 47.728

8.  Proteins specified by herpes simplex virus. IX. Contiguity of host and viral proteins in the plasma membrane of infected cells.

Authors:  J W Heine; B Roizman
Journal:  J Virol       Date:  1973-05       Impact factor: 5.103

9.  Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpesvirion.

Authors:  P G Spear; B Roizman
Journal:  J Virol       Date:  1972-01       Impact factor: 5.103

10.  The fate of sensitized equine arteritis virus following neutralization by complement of anti-IgG serum.

Authors:  A I Radwan; D Burger; W C Davis
Journal:  Virology       Date:  1973-06       Impact factor: 3.616

View more
  5 in total

1.  Geographical distribution of the herpes simplex virus type 1 BgKL variant in Japan suggests gradual dispersion of the virus from Shikoku Island to the other Islands.

Authors:  Shigeru Ozawa; Hiroyuki Eda; Kozaburo Hayashi; Kamesaburo Yoshino; Kazuo Yanagi
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

2.  Thermal-pH inactivation of herpes simplex virus: interdependence of the medium composition and the pH on the rate of virus inactivation. Brief report.

Authors:  G Lancz; J Sample
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

3.  Destabilization of herpes simplex virus type 1 virions by local anesthetics, alkaline pH, and calcium depletion.

Authors:  K Yanagi; S Harada
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

4.  The herpes simplex virus type 1 BgKL variant, unlike the BgOL variant, shows a higher association with orolabial infection than with infections at other sites, supporting the variant-dispersion-replacement hypothesis.

Authors:  Shigeru Ozawa; Hiroyuki Eda; Yasuyuki Ishii; Fumihiko Ban; Toshiyuki Funabashi; Seiichiro Hata; Kozaburo Hayashi; Hiroki Iga; Takao Ikushima; Hiroaki Ishiko; Tomoo Itagaki; Rinji Kawana; Shunsaku Kobayashi; Takeo Ogino; Tsuyoshi Sekizawa; Yoshikazu Shimomura; Hiroshi Shiota; Ryoichi Mori; Takashi Nakakita; Yoshio Numazaki; Yoshikatsu Ozaki; Shigeru Yamamoto; Kamesaburo Yoshino; Kazuo Yanagi
Journal:  J Clin Microbiol       Date:  2007-05-02       Impact factor: 5.948

5.  The UL13 and US3 Protein Kinases of Herpes Simplex Virus 1 Cooperate to Promote the Assembly and Release of Mature, Infectious Virions.

Authors:  Svetlana Gershburg; Joshua Geltz; Karin E Peterson; William P Halford; Edward Gershburg
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.